Dosage Forms & Drug Delivery Systems – Page 26

E&L Failure after packaging change: sampling, filtration, and EM controls

Detecting E&L failures typically begins with observing symptoms either on the manufacturing floor or during laboratory evaluations. While some signs may be obvious, others require detailed examination to fully understand…

Dose Delivery Variability at accelerated stability: process parameter review and validation impact

The initial stage of any investigation begins with identifying clear symptoms or signals indicating dose delivery variability. Symptoms may manifest in a variety of ways:Click to read the full article.

Ph Drift during bulk hold: cleaning validation and worst-case selection

The first step in addressing pH drift is identifying the symptoms or signals that indicate an issue. Symptoms of pH drift can manifest in various ways and should be closely…

Dose Delivery Variability during EU/UK market supply: inspection-ready documentation pack

Identifying symptoms of dose delivery variability is the first step in any deviation investigation. Early detection can prevent broader quality issues and regulatory repercussions. Common symptoms may include:Click to read…

Ccit Failure during terminal sterilization: FDA/MHRA investigation narrative and batch impact

When a Ccit (Chemical Indicator Test) failure occurs during terminal sterilization, several symptoms may surface. Identifying these signals early is essential for prompt containment and investigation. Common symptoms include:Click to…

Particulate Matter Oos for multi-dose products: sampling, filtration, and EM controls

Symptoms or signals indicating the presence of particulate matter typically include abnormal findings during routine inspections, customer complaints, or unexpected OOS results during stability testing or routine quality control (QC)…

Ivpt Failure in transdermal patch manufacturing: GMP investigation plan and CAPA

Identifying symptoms that indicate an Ivpt failure in transdermal patch manufacturing is the first step in a successful investigation. Signs include:Click to read the full article.

Assay Oos after adhesive change: GMP investigation plan and CAPA

Investigation Plan and CAPA for Assay OOS Following Adhesive Change Investigating Out-of-Specification (OOS) assay results after an adhesive change presents a critical challenge in pharmaceutical manufacturing. Such deviations can signify…

Packaging Dry-Out during die-cutting: inspection-ready documentation pack

Identification of symptoms is the first critical step in managing any deviation or OOS situation. In the case of packaging dry-out during die-cutting, various signals may be observed, including:Click to…

Pet Failure during PAI readiness: CAPA and effectiveness check plan

Pet failures can manifest in several ways, including but not limited to:Click to read the full article.

Dose Delivery Variability in transdermal patch manufacturing: inspection-ready documentation pack

Addressing Dose Delivery Variability in the Manufacturing of Transdermal Patches Dose delivery variability in transdermal patch manufacturing presents significant challenges, often manifesting as deviations or out-of-specification (OOS) results. This article…

Edge Lifting after adhesive change: GMP investigation plan and CAPA

When edge lifting occurs, it presents itself through various observable signals both during the manufacturing process and in quality control testing. Key symptoms may include:Click to read the full article.